Vivoryon Therapeutics N.V. (AMS:VVY)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
1.390
-0.030 (-2.11%)
Mar 5, 2026, 5:35 PM CET
-28.72%
Market Cap 42.05M
Revenue (ttm) n/a
Net Income (ttm) -12.48M
Shares Out 29.61M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 42,030
Average Volume 36,648
Open 1.370
Previous Close 1.420
Day's Range 1.370 - 1.390
52-Week Range 1.352 - 2.000
Beta 1.52
RSI 43.12
Earnings Date Apr 24, 2026

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 14
Stock Exchange Euronext Amsterdam
Ticker Symbol VVY
Full Company Profile

Financial Performance

Financial Statements

News

Vivoryon Therapeutics NV (WBO:VVYN) Q3 2025 Earnings Call Highlights: Strategic Advances and ...

Vivoryon Therapeutics NV (WBO:VVYN) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Management Shine Amid Challenges

3 months ago - GuruFocus

Q3 2025 Vivoryon Therapeutics NV Earnings Call Transcript

Q3 2025 Vivoryon Therapeutics NV Earnings Call Transcript

3 months ago - GuruFocus

Vivoryon Therapeutics N.V. (VIVRF) Q3 2025 Earnings Call Transcript

Vivoryon Therapeutics N.V. (OTC:VIVRF) Q3 2025 Earnings Call December 4, 2025 9:00 AM ESTCompany ParticipantsJulia Neugebauer - Chief Operating Officer...

3 months ago - Seeking Alpha

Vivoryon Therapeutics NV (FRA:05Y) (H1 2025) Earnings Call Highlights: Strategic Advances Amid ...

Vivoryon Therapeutics NV (FRA:05Y) (H1 2025) Earnings Call Highlights: Strategic Advances Amid Financial Challenges

6 months ago - GuruFocus

Half Year 2025 Vivoryon Therapeutics NV Earnings Call Transcript

Half Year 2025 Vivoryon Therapeutics NV Earnings Call Transcript

6 months ago - GuruFocus

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Challenges

1 year ago - GuruFocus

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

1 year ago - GuruFocus